Pfizer's inclacumab fails Phase III study for sickle cell disease, disappointing the community while the company remains ...

Most important is anti-blood-clot medicine Eliquis, which is due to lose patent exclusivity in 2026. Eliquis emerged last year as Pfizer’s top-performing drug, having grown rapidly to bring in $7.4bn ...

Pfizer (NYSE: PFE) is a case in point, with its forward dividend yield of 7%. Although the stock is a favorite for many ...

Summit Therapeutics, which has consistently been communicating quarterly results through investor calls in the past few years ...

Strand Therapeutics has raised $153 million in second-round financing that will be used to move its programmable mRNA ...

At first glance, Pfizer delivered a strong Q2 and upped its 2025 full-year EPS guidance. Click here to find out why I rate ...

While Pfizer remains on track for an impressive $7.2 billion in cost cuts by the end of 2027, we think the market is more ...

David Denton, CFO and EVP of Pfizer: “Our robust second-quarter Revenue and EPS performance demonstrates our continued focus on commercial execution and operational efficiency. We raised our full-year ...

Bourla noted during the call that Pfizer is looking into potential combination treatment strategies, for example, pairing SSGJ-707 with its antibody-drug conjugates, and will announce plans later this ...

Earlier this year, it signed a licensing agreement with China-based 3SBio for SSGJ-707, an investigational bispecific antibody -- a niche that is increasingly gaining ground in oncology.

Earlier this year, it signed a licensing agreement with China-based 3SBio for SSGJ-707, an investigational bispecific antibody -- a niche that is increasingly gaining ground in oncology.

Excitement builds for the 707 National Sailing Championship, happening at Port Edgar Yacht Club under the iconic Forth Bridges from July 31st to August 3rd!